About
Novel immunomodulatory enzymes for transplantation and acute autoimmune diseases
Areas of Focus
Categories
DiagnosticsBiologics & Biopharmaceutical
Clinical Trials (22)
View allTotal Trials
22
As Lead Sponsor
18
As Collaborator
4
Total Enrollment
1,284
By Phase
PHASE2: 10PHASE3: 6PHASE1: 2PHASE1/PHASE2: 1
By Status
COMPLETED: 10RECRUITING: 5ACTIVE_NOT_RECRUITING: 3TERMINATED: 3ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline22 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06518005Collaborator
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
PHASE2Recruiting
3 participants
Started: Nov 8, 2024 · Completed: Sep 30, 2030
NCT06205797Lead Sponsor
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
PHASE3Recruiting
312 participants
Started: Jun 20, 2024 · Completed: Mar 31, 2025
NCT06241950Collaborator
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
PHASE1Enrolling by invitation
6 participants
Started: Jan 29, 2024 · Completed: Oct 31, 2027
NCT05964257Lead Sponsor
To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy
PHASE3Active, not recruiting
188 participants
Started: Jul 25, 2023 · Completed: May 30, 2025
NCT05937750Lead Sponsor
A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group
PHASE3Recruiting
150 participants
Started: Jul 3, 2023 · Completed: Apr 30, 2030
Locations (1)
Headquarters
Lund, Sweden
Map
Loading map...